Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 5/20 | 0.54 |
| ▸ | CNR1 | P21554 | 7/20 | 0.52 |
| ▸ | CNR2 | P34972 | 5/20 | 0.52 |
| ▸ | CFD | P00746 | 4/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17324729 | 0.88 | CNR1 (0.44) | HTR3ACNR1CNR2CFDGLS | |
| SCHEMBL17324753 | 0.85 | CNR1 (0.48) | HTR3ACNR1CNR2CFDGLS | |
| SCHEMBL17324780 | 0.84 | ROCK1 (0.48) | HTR3ACNR1CNR2CFDGLS | |
| SCHEMBL17324818 | 0.84 | KDM4C (0.50) | HTR3ACNR1CNR2KDM4ETSHR | |
| SCHEMBL17170596 | 0.84 | HTR3A (0.54) | HTR3ACNR1CNR2KDM4ETSHR | |
| SCHEMBL17176590 | 0.82 | HTR3A (0.57) | HTR3ACNR1CNR2CFDTSHR | |
| SCHEMBL17176491 | 0.82 | HTR3A (0.59) | HTR3ACNR1CNR2CFDKDM4E | |
| SCHEMBL17324730 | 0.81 | CNR1 (0.48) | HTR3ACNR1CNR2PARP1KDM4E | |
| SCHEMBL12481560 | 0.81 | HSD17B10 (0.61) | CFDKDM4EHSD17B10 | |
| SCHEMBL29781847 | 0.81 | HSD17B10 (0.61) | CFDKDM4EHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9695195-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-07-04 | — | — | US | disclosed |
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL (JP) | 2016-06-30 | — | — | US | disclosed |
| US-9303045-B2 | 5-HT3 receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-04-05 | — | — | US | disclosed |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185801-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885CNR1 37/4885CNR2 47/4885 |
| US-20150291624-A1 | 5-HT3 RECEPTOR ANTAGONISTS | HTR3A, HTR5A, HTR3B | HTR3A 1/4885CNR1 37/4885CNR2 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.